In approximately 90% of cases, the cause of a fatal or a nonfatal myocardial infarction (MI) or stroke is a blood clot in a coronary artery (coronary thrombosis) or cerebral artery (cerebral thrombosis). The clot often occurs on the surface of a plaque of atheroma that is partially obstructing the lumen of the coronary artery. Patients may have many large atheromatous plaques and yet do not develop a clot over a 5–40-year period. There is no test that can tell us when and where a clot will occur.
Prevention of atheroma formation in arteries; prevention of erosion or rupture of atheromatous plaques in the coronary arteries and cerebral circulation. Plaque rupture liberates highly thrombogenic substances that rapidly cause clotting and blockage of arteries.
Clot-dissolving drugs (thrombolytic agents).
Agents that prevent clot formation ( anticoagulants...
- ASSENT-2 Investigators (1999) Assessment of the Safety and Efficacy of a New Thrombolytic: single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomized trial. Lancet 354:716Google Scholar
- Jolly SS, Faxon DP, Fox KA et al (2009) Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (fifth organization to assess strategies in ischemic syndromes) Trial. J Am Coll Cardiol 54:468–476PubMedGoogle Scholar
- ASSENT-3 (2001) The ASSENT-3 randomized trial in acute myocardial infarction. Lancet 358:605–613. ASSENT-3Google Scholar
- GISSI: Italian Group (1986) Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1:397. GISSIGoogle Scholar
- GUSTO Investigators (1993) An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329:673. GUSTOGoogle Scholar
- ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither, among 17,187 cases of suspected acute myocardial infarction. Lancet 2:350. ISIS-2Google Scholar
- The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (2006) Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354:1464–1476. The OASIS-5Google Scholar
- The OASIS-6 Trial Group (2006) Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction. The randomized trial. JAMA 295:1519–1530. OASIS-6Google Scholar